Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 10, 1996, Pages 415-419

  Tanaka, M ^a   Yamazaki, H ^a   Ryokawa, Y ^a   Hakusui, H ^a   Nakamichi, N ^b   Sekino, H ^c  

^a DAIICHI SANKYO CO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Sekino Hospital   (Japan)

Author keywords

Dose linearity; Japanese volunteers; Pantoprazole; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENTERIC COATED TABLET; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; SORE THROAT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BLOOD CHEMICAL ANALYSIS; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; JAPAN; MALE; OMEPRAZOLE; SULFOXIDES; TABLETS, ENTERIC-COATED;

EID: 0029842029     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Andersson T, Cederberg C, Rega°rdh C, Ska°nberg I 1990a Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 39: 195-197
2. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P 1990b Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47: 79-85
3. Andersson T, Rega°rdh C, Dahl-Puustinen M, Bertilsson L 1990c Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 451-416
4. Andersson T, Andren K, Cederberg C, Langerström PO, Lundborg P, Ska°nberg I 1990d Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmcol 29: 557-563
5. +-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 32: 44-50
6. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T 1993 Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′ -hydroxylation. J Pharmacol Exp Ther 266: 52-59
7. +-ATPase inhibitor (BY 1023/SK&F 96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up. J Chromatogr 529: 389-401
8. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regardh CG, Lau YC, Zhang Y, Dahl ML, Bertilsson L 1994 Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16: 214-215
9. Pue MA, Laroche J, Meineke I, de May C 1993 Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44: 575-578
10. +)-ATPase inhibitor. Biochem Pharmacol 39: 1799-1806
11. Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann R, Wurst W 1990b Effect of repeated oral administration of BY 1023/SK&F 96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 373-379
12. +-ATPase-inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers. Z Gastroenterol 28: 443-447
13. Simon WA 1995 Pantoprazole - which cytochrome P450 isozymes are involved in its biotransformation? Gut 37 (Suppl 2): A135
14. Sohn DR, Shin SG, Ishizaki T 1994 S-mephenytoin pharmacogenetics and its clinical implications in Asian ethnic populations. Asia Pacific J Pharmacol 9: 287-301
15. Tanswell P, Koup J 1993 TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol 31: 5l4-520